You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 The scores of evaluating 7 guidelines by AGREE instrument

From: Analysis of the Status of Chinese clinical practice guidelines development

AGREE Domain Asthma (1997)a COPDb Hyper-tensionc AMId Asthma (2003)e HAPf OSAHSg Average Score
scope and purpose (%) 16.7 27.8 66.7 55.6 16.7 72.2 33.3 41.3
stakeholder involvement (%) 4.2 0.0 54.2 12.5 0.0 0.0 0.0 10.1
rigor of development (%) 14.3 16.7 28.6 45.2 14.3 2.4 14.3 19.4
clarity and presentation (%) 95.8 95.8 100.0 83.3 83.3 75.0 95.8 89.9
Applicability (%) 16.7 27.8 50.0 16.7 22.2 11.1 16.7 23.0
editorial independence (%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0%
Spearman correlation coefficient 0.754 0.600 0.493 0.472 0.569 0.789 0.835  
Sig.(2-tailed) <0.01 <0.01 <0.05 <0.05 <0.01 <0.01 <0.01  
  1. Note:
  2. a. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 1997).
  3. b. the Guidelines for Diagnosis and Treatment of COPD.
  4. c. the Guidelines for Prevention and Treatment of Hypertension in China (produced in 1999).
  5. d. the Guidelines for Diagnosis and Treatment of Acute Myocardial Infarction (AMI) [7].
  6. e. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 2003) [8].
  7. f. the Guidelines for Diagnosis and Treatment of Hospital Acquired Pneumonia (HAP) [9].
  8. g. the Guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS-Draft) [10].